RTP biotech Incyclix, which is targeting cancer, adds another $3M in funding

RESEARCH TRIANGLE PARK – Incyclix, an emerging biotech focusing on the fight against cancer, has secured nearly $3 million in a $30 million round announced in 2022.

In an SEC filing, the company, whose founders include PPD Inc. founder and investor Fred Eshelman, says funding will be added incrementally to the original $12 million in equity already disclosed.

“The offering is fully subscribed and the remaining $15,047,001 of the securities will automatically close upon the achievement of a specified milestone,” the SEC filing states.

Incyclix focuses on producing small molecule inhibitors of cyclin-dependent kinases (CDKs) to attack advanced and treatment-resistant cancers. The uncontrolled cellular growth that is a hallmark of the disease is commonly caused by the activity of various types of CDK.

Here is a link to the profile of the company published last year: